These findings advance our understanding of CML pathophysiology and establish a foundation for the development of innovative therapeutic approaches targeting the ZFAS1/STAT3 axis. This evidence concerns the gene ZFAS1 and chronic myelogenous leukemia, BCR-ABL1 positive.